114 results about "Stimulant" patented technology

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a "therapeutic component"), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.

The invention provides a preparation composition of a glucagon-like peptide-1 receptor agonist for nasal mucosa administration, and particularly relates to the technical field of biological medicine materials. The preparation composition mainly comprises a glucagon-like peptide-1 receptor stimulant, alkyl glycoside and phospholipid, wherein the ratio of the glucagon-like peptide-1 receptor stimulant to the alkyl glycoside to the phospholipid is (0.25-17.5): (0.25-10): (0.1-10) by mass. The active pharmaceutical ingredients in the preparation composition provided by the invention are delivered through nasal mucosa, directly enter blood circulation from an absorption part, can take effect quickly, have higher bioavailability, and improve the compliance of patients.

Methods, devices, and systems are disclosed for controlled delivery of a therapy, such as a stimulant, to a mouth of a subject via an oral device positioned in a secured configuration in the mouth. At least one of a tongue position stimulator (TST) and tongue position sensor (TSE) is provided, according to certain aspects. According to another aspect, a stimulus is delivered to the mouth and / or tongue via a mouthpiece secured to the subject's teeth. In another regard, a stimulus is delivered that generates a natural response to eliminate or reduce sleep disorders, such as for example at least one of snoring and obstructive sleep apnea.

Provided herein are carbamothioate and carbamodithioate derivatives of 3,4-methylenedioxymethamphetamine (MDMA), and its stereoisomers (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine, and pharmaceutical compositions thereof, as well as a high purity process for the preparation of the parent compounds, wherein MDMA is a synthetic drug possessing both stimulant and mild hallucinogenic properties. Such derivatives could be used for treating or preventing a disease, disorder, or condition in which an increased level of 3,4-methylenedioxymethamphetamine is beneficial.

The invention provides an application of alpha-melanocyte stimulant in treating asthma by inhibiting type II innate lymphocytes. An IL-7R-STAT pathway in activated lung ILC2 is inhibited through an alpha-MSH-MC5R axis, it is found that the neuroendocrine hormone alpha-MSH can target ILC2 to limit lung inflammation, and screening of new drugs for treating lung inflammation is facilitated.

The invention belongs to the technical field of chemical pharmacy, and particularly relates to a preparation method and application of an impurity of a beta2 adrenal receptor stimulant and M receptor antagonist bifunctional active compound. According to the impurity preparation method of the beta2 adrenal receptor stimulant and M receptor antagonist bifunctional active compound, acetylation of amino is successfully realized by using acetylation reagents such as acetyl chloride and alkali accelerators such as N, N-diisopropylethylamine, then debenzylation is performed through hydrogenation reaction, and the compound shown in the formula I is successfully prepared. Then, through liquid chromatography purification, a high-purity compound as shown in the formula I is obtained, and the raw material medicine as shown in JKN2304 can meet the requirements of reference substances in the research and development process; the technical problem that in the prior art, an impurity synthesis process of a beta 2 adrenal gland receptor agonist and M receptor antagonist bifunctional active compound is lacked is solved.

Disclosed herein are compositions that include a combination of: (1) a non-caffeine stimulant or nootropic (e.g., paraxanthine); (2) a ketone body or ketone body precursor, such as beta-hydroxybutyrate (BHB) salt, BHB ester, BHB acid, acetoacetate salt, acetoacetate ester, acetoacetic acid, 1,3-butanediol, medium chain fatty acid, or ester of medium chain fatty acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. The composition may include a vasodilator. The composition may include a short or medium chain fatty acid or ester thereof in addition to or instead of the ketone body or ketone body precursor. The composition can provide enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. The composition can also beneficially increase resting energy expenditure (resting metabolic rate), particularly when in a state of ketosis, enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy / lightheadedness when entering a ketogenic state.

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

The invention provides a pharmaceutical composition. The pharmaceutical composition is composed of a thyroxine receptor beta agonist, folic acid substances and pharmaceutically acceptable auxiliary materials. The invention also relates to application of the composition in preparation of drugs for treating chronic fatty liver diseases. The pharmaceutical composition has the advantages that the pharmaceutical composition can be used for treating the fatty liver accompanied by hypothyroidism, and adverse reactions generated by independently taking a thyroid receptor beta agonist can be reduced.

The present invention relates to a pharmaceutical composition and the like containing a stimulant for PWAR5 expression as an active ingredient for preventing or treating infectious diseases due to hepatitis C virus, the present invention allowing the PWAR5 level to be sustained at a high level inside the cell to effectively inhibit proliferation of HCV.

Described herein are new dual sigma receptor and dopamine transporter small molecule antagonists. As these compounds are antagonists of both sigma receptors and dopamine transporters, these compounds dose-dependently antagonize stimulant self-administration and also diminish the effects of stimulant effects on dopamine level, thus indicating minimal abuse liability.

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and / or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and / or rapid dissolution / degradation in a physiological environment (e.g., intestinal environment) and / or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution / degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and / or enhancement agents with a structural material necessary for gastric residence but configured for controlled and / or tunable degradation / dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

The invention relates to the technical field of cell detection kits, and particularly discloses a cell proliferation detection kit, which comprises: a base; the top seat is arranged above the base; the positioning assembly is connected with the partition plates and the top seat, so that the states of the partition plates can be conveniently adjusted, according to the cell proliferation culture requirements, drugs or irritants with different concentrations can be conveniently added into the reagent tubes, and an experimenter can move the top seat; the partition plates are simultaneously connected with the top seat and the base to form a parallelogram structure; the reagent tubes in the holes of the pore plate are inclined at the same time, so that an experimenter can add a reagent according to the reagent tubes which are inclined at the same time, the experiment process is simplified, the test efficiency is improved, the reagent is added by obliquely attaching the partition plate walls, bubbles can be prevented from being generated under the liquid level, and good wall attachment of the reagent is ensured; and the problems of aggregation and interference on experimental determination caused by severe oscillation of cells possibly caused by taking out the reagent tube are effectively avoided.

A neurite growth stimulant is a small molecule ENPP1 inhibitor. Small molecule ENPP1 inhibitors are capable of treating central nervous system (CNS) injury and promoting axonal regeneration. The ENPP1 inhibitor in the carrier can be administered at damaged nerves and their cell bodies to promote the regeneration of axons.

The invention discloses a substance with anti-allergic activity and application thereof, the substance with anti-allergic activity is a bitter receptor stimulant, and the bitter receptor stimulant is selected from at least one of denatonium benzoate, difenidol and quinine. The compound can reduce the expression level of IgE in serum, inhibit mast cell degranulation and regulate and control expression of cytokines at the downstream of Th1, Th2 and Dc cells, so that allergy is prevented and allergic symptoms are relieved, and the compound can be used for preparing medicines, health foods, functional foods and dietary supplements for preventing and relieving food allergy.

The invention discloses a method for preparing a biostimulant from a hydrothermal carbonization solution. The method comprises the following steps: hydrothermal carbonization of biomass wastes, dilution of the hydrothermal carbonization solution, domestication of activated sludge and enhancement of synergistic functional bacteria, and aerobic treatment. The invention also discloses an application effect of the hydrothermal carbonization liquid. By means of the method, substances which are toxic to crop growth in the hydrothermal carbonization liquid can be effectively removed, a biostimulant functional product which has a promoting effect on crop growth is prepared, the technological process is green and environmentally friendly, the raw material adaptability is wide, the technology is stable, and good application prospects are achieved.

A method for detecting an immune cellular response including the steps of: (a) suctioning a defined amount of the sample by an automated suction / discharge device, (b) discharging this amount, using the device, into container R, containing, beforehand, at least one stimulant for secretion of the molecule by the at least one cell, or else not containing such a stimulant, (c) when the container does not contain the stimulant beforehand, introducing into container R the at least one secretion stimulant contained in container E, using the device, and (d) allowing the sample and stimulant to incubate, forming a mixture, by the at least one cell (i) in container R or (ii) in another container S after suctioning and discharge of the mixture using the device, and (e) detecting the immune cellular response, the detection of the immune cellular response indicates the presence of an immune cellular response specific for the stimulant.

The invention relates to a medicine with drug rehabilitation and relapse prevention effects as well as a preparation method and application thereof, and belongs to the field of medicines. The medicine comprises rotundine and salts and is prepared through a chemical synthesis method, and experiments prove that the medicine preparation has the effects of treating opioid substances including heroin, morphine, dolantin, methadone and the like as well as other psychoactive substances, such as opioid and the like. Independent or addiction formed by cocaine, amphetamine stimulants, wine, smoke, cannabis sativa, sedative and hypnotic drugs and the like has the effects of detoxifying, relieving symptoms, inhibiting psychological craving and reducing relapse rate.

The invention discloses traditional Chinese medicine instant granules as well as a preparation method and application thereof. The traditional Chinese medicine instant granules are prepared from the following raw materials in parts by mass: 20-60 parts of traditional Chinese medicine components, 60-200 parts of a filling agent, 20-60 parts of a disintegrating agent and 5-30 parts of an adhesive. Different from traditional soluble granules, on one hand, the moisturizing-free instant granules are used for oral administration without a large amount of solvent, can be quickly dissolved in a very small amount of water, and can be almost completely dissolved within 5 seconds to form tiny granules; on the other hand, saliva irritants are not needed. The traditional Chinese medicine instant granules take traditional Chinese medicines as medicinal components, can contain various natural herbaceous plant micro powder or extracts, such as platycodon grandiflorum, liquorice and other components with the effects of relieving cough, eliminating phlegm, diminishing inflammation, easing pain and the like, and can directly act on the throat mucosa; and the ginseng, the astragalus membranaceus and other components with the effects of regulating immunity, tonifying middle-Jiao and Qi and the like can be quickly dissolved and then effectively absorbed.

To provide an alcoholic beverage that achieves reduction in stimulation from alcohol and / or an odd flavor of alcohol after drinking.SOLUTION: An alcoholic beverage includes cinnamaldehyde and / or terpinyl acetate.SELECTED DRAWING: None

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).

In certain embodiments, a parenteral formulation is disclosed comprising a compound of formula (I) disclosed herein and a pharma- ceutically acceptable excipient, wherein the formulation maintains at least 90% of the compound after accelerated storage conditions of 25° C., at 60% relative humidity for 2 weeks.

The invention discloses an integrated device with rubber tapping and stimulant smearing functions. The integrated device comprises a magnetic attraction supporting guide rail, a circumferential sliding device, a lifting control device and a multifunctional execution device. The multifunctional execution device comprises a rubber tapping execution assembly and a brush head execution assembly, in the rising stroke, the rubber tapping execution assembly conducts rubber tapping operation, and meanwhile the brush head execution assembly conducts dry brushing pre-cleaning on the surface of a rubber tapping tree below a rubber tapping opening along with the movement track; in the descending stroke, the brush head execution assembly smears the stimulation liquid on the surface of the pre-cleaned rubber tapping tree, and meanwhile the rubber tapping execution assembly is reset; the rubber tapping execution assembly and the brush head execution assembly are installed in the same device, the rubber tapping function and the stimulation liquid smearing function are integrated in the same device, multiple purposes are achieved through one machine, the working efficiency is remarkably higher than that of manual work, the labor intensity is greatly reduced, precise delayed smearing after rubber tapping is achieved through program control, the stimulation effect is stable, and the application range is wide. The rubber yield can be improved.

The invention belongs to the technical field of cosmetic detection, and discloses a method and a kit for evaluating the stimulation degree of stimulants to eyes, the method comprises the following steps: (1) dividing zebrafish juvenile fishes which are normally hatched after fertilization into two groups, namely a control group and a sample group, the control group is zebrafish juvenile fishes which are not treated by stimulants, the sample group is zebrafish juvenile fishes which are not treated by stimulants, and the sample group is zebrafish juvenile fishes which are not treated by stimulants; the sample group is a treatment group containing to-be-evaluated irritants; and (2) a qPCR method is used for measuring the expression level of genes related to the stimulation degree of zebra fish eyes in each group, the eye stimulation degree of irritants is evaluated according to the expression condition of mRNA of the genes, grading is carried out, and the measured genes comprise three genes, namely kdrl, flt4 and tnf alpha. The invention designs a new method for evaluating the stimulation degree of the irritant to the eyes, and realizes rapid and accurate stimulation degree grading of the to-be-evaluated irritant.

The subject matter disclosed generally relates to phenethylamines or cathinones covalently bound to a chemical moiety in a prodrug form. The presently described technology allows slow / sustained / controlled delivery of the parent phenethylamines or cathinones into the blood system in a manner that increase the duration of therapeutic efficacy, ease of application, patient compliance and / or a combination of these characteristics when administered, in particular, orally. Additionally, the described technology allows gradual release of the parent phenethylamines or cathinones over an extended period of time thereby eliminating spiking of drug levels which lessen cardiovascular stress, addiction / abuse potential and / or other common stimulant side effects associated with psychoactive compounds.

The utility model discloses a snore-ceasing patch, which relates to the technical field of medical supplies and comprises a snore-ceasing patch body, a cutting groove is arranged at the top end of the snore-ceasing patch body, and an arc-shaped groove is arranged on one side of the cutting groove. A first plaster sheet is arranged at the top end of the snore stopping sheet body and fixedly connected to the top end of the snore stopping sheet body, a second plaster sheet is arranged at the bottom end of the snore stopping sheet body, and absorbent cotton is arranged on the inner side of the second plaster sheet. The first plaster sheet is arranged at the top end of the snore stopping sheet body, mild medicine is arranged on the inner side of the first plaster sheet, the sedation effect can be effectively improved after a patient inhales the medicine, the sleep quality is improved, the second plaster sheet is arranged at the bottom end of the snore stopping sheet body, the medicine cotton is arranged on the inner side of the second plaster sheet, and the snore stopping sheet is convenient to use. The refreshing agent is arranged in the pillow, so that the respiratory capacity in sleep can be effectively increased, the breathing quality is improved, and the sleep quality is effectively improved.